Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis
Background The number of clinical studies evaluating the benefit of cytokine-induced killer cell (CIK) therapy, an adoptive immunotherapy, for colorectal cancer (CRC) is increasing. In many of these trials, CIK therapy was coadministered with conventional cancer therapy. The aim of this review is to...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-04-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/11/4/e006764.full |
| _version_ | 1797837383522058240 |
|---|---|
| author | Jun Li Timothy Price Eric Smith Paul Drew Guy J Maddern Celine Man Ying Li Yoko Tomita Bimala Dhakal Runhao Li Kevin Aaron Fenix |
| author_facet | Jun Li Timothy Price Eric Smith Paul Drew Guy J Maddern Celine Man Ying Li Yoko Tomita Bimala Dhakal Runhao Li Kevin Aaron Fenix |
| author_sort | Jun Li |
| collection | DOAJ |
| description | Background The number of clinical studies evaluating the benefit of cytokine-induced killer cell (CIK) therapy, an adoptive immunotherapy, for colorectal cancer (CRC) is increasing. In many of these trials, CIK therapy was coadministered with conventional cancer therapy. The aim of this review is to systematically assess the available literature, in which the majority were only in Chinese, on CIK therapy for the management of CRC using meta-analysis and to identify parameters associated with successful CIK therapy implementation.Methods Prospective and retrospective clinical studies which compared CIK therapy to non-CIK therapy in patients with CRC were searched for electronically on MEDLINE, Embase, China National Knowledge Infrastructure, and Wanfang Data databases. The clinical endpoints of overall survival (OS), progression-free survival (PFS), OS and PFS rates, overall response rate (ORR), and toxicity were meta-analyzed using HR and relative ratio (RR), and subgroup analyses were performed using chi-square (χ2) test and I-squared (I2) statistics for study design, disease stage, cotherapy type, and timing of administration.Results In total, 70 studies involving 6743 patients were analyzed. CIK therapy was favored over non-CIK therapy for OS (HR=0.59, 95% CI: 0.53 to 0.65), PFS (HR=0.55, 95% CI: 0.47 to 0.63), and ORR (RR=0.65, 95% CI: 0.57 to 0.74) without increasing toxicity (HR=0.59, 95% CI: 0.16 to 2.25). Subgroup analyses on OS and PFS by study design (randomized vs non-randomized study design), disease stage (Stage I–III vs Stage IV), cotreatment with dendritic cells (DCs) (CIK vs DC-CIK therapy), or timing of therapy administration (concurrent vs sequential with coadministered anticancer therapy) also showed that the clinical benefit of CIK therapy was robust in any subgroup analysis. Furthermore, cotreatment with DCs did not improve clinical outcomes over CIK therapy alone.Conclusion Compared with standard therapy, patients who received additional CIK cell therapy had favorable outcomes without increased toxicity, warranting further investigation into CIK therapy for the treatment of CRC. |
| first_indexed | 2024-04-09T15:24:59Z |
| format | Article |
| id | doaj.art-99d254a647f247678e111f964edcfc9e |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-04-09T15:24:59Z |
| publishDate | 2023-04-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-99d254a647f247678e111f964edcfc9e2023-04-28T22:00:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-04-0111410.1136/jitc-2023-006764Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysisJun Li0Timothy Price1Eric Smith2Paul Drew3Guy J Maddern4Celine Man Ying Li5Yoko Tomita6Bimala Dhakal7Runhao Li8Kevin Aaron Fenix92 Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai, ChinaThe Queen Elizabeth Hospital, Oncology, 28-Woodville Road, Woodville South, Adelaide, South Australia, 5011, AustraliaAff1 grid.51462.340000000121719952Memorial Sloan Kettering Cancer Center 300 E 66th Street, BAIC 813 10065 New York NY USA4 Department of Language and Linguistic Science, University of York, York, North Yorkshire, UKUniversity of Adelaide, Discipline of Surgery, The Queen Elizabeth Hospital, Adelaide, South Australia, AustraliaDiscipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, AustraliaBasil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South, South Australia, AustraliaDiscipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, AustraliaBasil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South, South Australia, AustraliaDiscipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, AustraliaBackground The number of clinical studies evaluating the benefit of cytokine-induced killer cell (CIK) therapy, an adoptive immunotherapy, for colorectal cancer (CRC) is increasing. In many of these trials, CIK therapy was coadministered with conventional cancer therapy. The aim of this review is to systematically assess the available literature, in which the majority were only in Chinese, on CIK therapy for the management of CRC using meta-analysis and to identify parameters associated with successful CIK therapy implementation.Methods Prospective and retrospective clinical studies which compared CIK therapy to non-CIK therapy in patients with CRC were searched for electronically on MEDLINE, Embase, China National Knowledge Infrastructure, and Wanfang Data databases. The clinical endpoints of overall survival (OS), progression-free survival (PFS), OS and PFS rates, overall response rate (ORR), and toxicity were meta-analyzed using HR and relative ratio (RR), and subgroup analyses were performed using chi-square (χ2) test and I-squared (I2) statistics for study design, disease stage, cotherapy type, and timing of administration.Results In total, 70 studies involving 6743 patients were analyzed. CIK therapy was favored over non-CIK therapy for OS (HR=0.59, 95% CI: 0.53 to 0.65), PFS (HR=0.55, 95% CI: 0.47 to 0.63), and ORR (RR=0.65, 95% CI: 0.57 to 0.74) without increasing toxicity (HR=0.59, 95% CI: 0.16 to 2.25). Subgroup analyses on OS and PFS by study design (randomized vs non-randomized study design), disease stage (Stage I–III vs Stage IV), cotreatment with dendritic cells (DCs) (CIK vs DC-CIK therapy), or timing of therapy administration (concurrent vs sequential with coadministered anticancer therapy) also showed that the clinical benefit of CIK therapy was robust in any subgroup analysis. Furthermore, cotreatment with DCs did not improve clinical outcomes over CIK therapy alone.Conclusion Compared with standard therapy, patients who received additional CIK cell therapy had favorable outcomes without increased toxicity, warranting further investigation into CIK therapy for the treatment of CRC.https://jitc.bmj.com/content/11/4/e006764.full |
| spellingShingle | Jun Li Timothy Price Eric Smith Paul Drew Guy J Maddern Celine Man Ying Li Yoko Tomita Bimala Dhakal Runhao Li Kevin Aaron Fenix Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis Journal for ImmunoTherapy of Cancer |
| title | Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis |
| title_full | Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis |
| title_fullStr | Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis |
| title_full_unstemmed | Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis |
| title_short | Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis |
| title_sort | use of cytokine induced killer cell therapy in patients with colorectal cancer a systematic review and meta analysis |
| url | https://jitc.bmj.com/content/11/4/e006764.full |
| work_keys_str_mv | AT junli useofcytokineinducedkillercelltherapyinpatientswithcolorectalcancerasystematicreviewandmetaanalysis AT timothyprice useofcytokineinducedkillercelltherapyinpatientswithcolorectalcancerasystematicreviewandmetaanalysis AT ericsmith useofcytokineinducedkillercelltherapyinpatientswithcolorectalcancerasystematicreviewandmetaanalysis AT pauldrew useofcytokineinducedkillercelltherapyinpatientswithcolorectalcancerasystematicreviewandmetaanalysis AT guyjmaddern useofcytokineinducedkillercelltherapyinpatientswithcolorectalcancerasystematicreviewandmetaanalysis AT celinemanyingli useofcytokineinducedkillercelltherapyinpatientswithcolorectalcancerasystematicreviewandmetaanalysis AT yokotomita useofcytokineinducedkillercelltherapyinpatientswithcolorectalcancerasystematicreviewandmetaanalysis AT bimaladhakal useofcytokineinducedkillercelltherapyinpatientswithcolorectalcancerasystematicreviewandmetaanalysis AT runhaoli useofcytokineinducedkillercelltherapyinpatientswithcolorectalcancerasystematicreviewandmetaanalysis AT kevinaaronfenix useofcytokineinducedkillercelltherapyinpatientswithcolorectalcancerasystematicreviewandmetaanalysis |